Gilead Sciences

News

NICE backs use of Gilead/Kite CAR-T via Cancer Drugs Fund

A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro

News

Gilead presses go on first Nurix protein degrader drug

Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.

News

Gilead gets big $175m judgment in HIV fraud case

Massive judgment takes the total awarded to the pharma company to nearly $250 million.

News

Gilead buoyed by Trodelvy OK in new breast cancer use

The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market

News

Gilead adds lupus, arthritis therapies with EVOQ alliance

US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<

News

Gilead grabs full rights to Jounce cancer immunotherapy

Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th

NICE backs use of Gilead/Kite CAR-T via Cancer Drugs Fund

Gilead presses go on first Nurix protein degrader drug

Gilead gets big $175m judgment in HIV fraud case

Gilead buoyed by Trodelvy OK in new breast cancer use

Gilead adds lupus, arthritis therapies with EVOQ alliance

Gilead grabs full rights to Jounce cancer immunotherapy

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Gilead Sciences

Editor's Picks